Ardelyx Investors Face November Deadline in Securities Class Action

The litigation centers on allegations that Ardelyx misrepresented the effectiveness of its prescription pull-through process. While the company maintained optimistic financial guidance, shareholders claim management failed to disclose how stringent payer utilization-management controls and step-edit requirements were hindering new-patient starts for the drug IBSRELA. The complaint suggests that the company’s internal hub, ArdelyxAssist, struggled to navigate these barriers despite public assurances that the firm would manage patient access internally.

The discrepancy surfaced on August 6, 2026, when Ardelyx reduced its full-year 2026 revenue guidance for IBSRELA and withdrew its long-term revenue projections for XPHOZAH. Citing "evolving market dynamics" and increased payer utilization hurdles, the company’s stock price reacted sharply, closing at $4.00 the following day—an 18% decline from its previous close of $4.87. Investors seeking to participate in the recovery process are encouraged to contact Joseph E. Levi at Levi & Korsinsky, LLP to review their eligibility.